SCIEX Advances the ZenoTOF Line With Platform-Wide Expansions in Software, Integrations, and Key Collaborations

Key Terms

data-independent acquisition technical

A laboratory method used in mass spectrometry to measure many proteins at once by systematically collecting data across all detectable molecules rather than targeting a few chosen ones. Think of it as taking a series of broad, high-resolution snapshots of a crowded scene so you can return later and reliably count and compare individual people. For investors, it matters because it enables more reproducible biomarker discovery, drug-target verification, and clinical data that can reduce development risk and strengthen regulatory or commercial claims.

proteomics medical

Proteomics is the large-scale study of all the proteins produced by a cell, tissue or organism, like taking a full inventory and watching how the workforce and machines inside a factory behave. For investors, proteomics matters because it helps identify drug targets, disease indicators and responses to treatments—information that can speed development, reduce risk, guide partnerships and reveal new commercial opportunities in biotech and diagnostics.

metabolomics medical

Study of the small molecules and chemical patterns produced by cells, tissues or body fluids, often described as the body’s short-term chemical “fingerprint.” It matters to investors because these fingerprints can reveal how a drug or treatment is working, identify disease markers, guide patient selection, or shorten development time—similar to using a snapshot to judge whether a machine is running efficiently and needs adjustment.

liquid chromatography technical

Liquid chromatography is a laboratory technique that separates, identifies and measures chemicals in a liquid sample by passing it through a material that slows different compounds by different amounts, like a filter that sorts marbles by size and weight. Investors care because it underpins drug development, quality control and diagnostics: reliable separation and measurement affect product safety, regulatory approval, manufacturing consistency and marketability.

biomarkers medical

Biomarkers are measurable indicators found in the body, such as substances in blood or tissues, that reveal information about health or disease. For investors, they can signal how well a medical treatment is working or whether a disease is developing, helping to assess the potential success or risks of healthcare companies or innovations. Think of biomarkers as biological signals that provide clues about a person’s health status.

hdx-ms medical

HDX‑MS (hydrogen–deuterium exchange mass spectrometry) is a lab technique that reveals which parts of a protein are exposed or change shape by swapping normal hydrogen atoms for a heavier form and then precisely “weighing” the pieces. For investors, HDX‑MS matters because it helps drug developers and biologics manufacturers verify a candidate’s structure, stability and how it binds targets—information that reduces scientific and regulatory risk much like a stress test reassures lenders about a loan’s safety.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MARLBOROUGH, Mass.--(BUSINESS WIRE)-- At ASMS, SCIEX, a Danaher company and leader in life science analytical technologies, introduced platform-wide advancements across its accurate mass ZenoTOF line. The updates include new SCIEX OS 5.0 software features, broader front-end compatibility, and forward-looking software collaborations designed to help omics researchers solve complex biological questions. This connected environment reduces workflow complexity, while enabling deeper, more actionable insights from a single, dynamic platform.

SCIEX OS 5.0 software introduces new features including Central Metrics Tracker, Central Monitoring, Reporter Template Creator, an AI enabled “helpme” function, and AI enabled Calculated Columns. Additional ZenoTOF line specific advancements include:

• ZT Scan DIA 3.0 combines the completeness of data-independent acquisition with narrower Q1 isolation windows so researchers can balance selectivity, sensitivity, and throughput based on the requirements of the experiment. This technology underpins scalable proteomics and robust metabolomics, reducing workflow complexity and expanding the range of applications a single platform can address.
  • With enhanced sensitivity mode on, the ZenoTOF 8600 system has demonstrated significant gains for low-input proteomics workflows with nanoflow, where improvements range from approximately 10% to 40% gains in both identification and quantitation.

Expanded front-end compatibility boosts the flexibility of the ZenoTOF line.

• Echo® MS+ system integration with the ZenoTOF 8600 system is the industry’s highest-throughput accurate mass platform, sampling at up to 1 sample per second. It delivers enhanced sensitivity for high-throughput screening, making it a foundational screening technology to accelerate early discovery, reduce complexity and consumable costs.
• HDX-MS by Trajan Scientific and Medical brings deep automation expertise and comprehensive data processing, unlocking deeper insights into protein structure and binding. These bookends complement EAD on the ZenoTOF line to deliver an integrated end-to-end solution for routine high-sensitivity, zero-scrambling, amino-acid residue resolved HDX-MS.
• New source enhancements deliver seamless compatibility between Evosep, IonOpticks, and the ZenoTOF line. Researchers can now fully leverage Whisper Zoom methods—bringing together high sensitivity, robustness, and throughput in a unified SCIEX-based platform to accelerate next-generation proteomics analyses. In addition, an agreement between SCIEX and IonOpticks plans to expand access to advanced liquid chromatography solutions for the proteomics community, including Aurora XS columns.

Key collaborations across leading software platforms enable researchers to operate within the workflows they already use and trust.

• A key collaboration brings BSI’s advanced AI-based proteomic PEAKS software data processing across the ZenoTOF line. It enables researchers to identify, quantify, and validate biomarkers in a single solution, and eliminates the traditional fragmentation between discovery and targeted quantitation, reducing complexity and improving reproducibility for translational research.
• MS-Dial becomes one of the pioneer collaborators translating ZT Scan DIA 3.0 measurements into life science answers. Customers can discover new biomarkers using this trusted life-sciences software package that profiles metabolomics and lipidomics.
• Collaboration with MZIO brings SCIEX data compatibility into mzmine, allowing users to integrate SCIEX into existing metabolomics and small molecule pipelines that support scalable data processing, advanced feature extraction, and downstream analysis across diverse MS workflows.

“Ultimately, we are not just delivering incremental performance — but a step change in how researchers can move across the omics continuum. This is just the beginning. Our commitment is simple - continuous innovation in this dynamic platform delivers for customers, across workflows,” says Jose Castro-Perez, Vice President of Product Management at SCIEX.

Learn more about the ZenoTOF line unlock at https://sciex.com/products/mass-spectrometers/qtof-systems/8600-system.

ABOUT SCIEX

SCIEX, a Danaher company and leader in life science analytical technologies, empowers our customers to solve the most impactful analytical challenges in quantitation and characterization. With groundbreaking innovation and outstanding reliability and support, SCIEX has been at the forefront of the field for over 50 years. ​

Since the launch of the first-ever commercially successful triple quadrupole in 1981, we continue to develop technologies and solutions that influence life-changing research and outcomes. That’s why thousands of life science experts around the world choose SCIEX to get the answers they can trust.

Advances in human wellness depend on the power of precise science.​

For more information, visit sciex.com. ​

Connect with us on LinkedIn, Facebook, and Instagram.​

ABOUT DANAHER

Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Through our connected ecosystem of industry-leading businesses, we work side by side with customers to solve their most complex scientific and clinical challenges—helping move innovations from discovery to delivery faster for patients who depend on them. Powered by the Danaher Business System, our advanced science and technology and proven ability to innovate help enable faster, more accurate diagnoses and reduce the time, cost, and risk required to discover, develop, and deliver life-changing therapies. Through continuous improvement and operational excellence, our approximately 60,000 associates worldwide are focused on delivering lasting impact and improving quality of life around the world, while building a healthier, more sustainable tomorrow. Explore more at www.danaher.com.

The SCIEX clinical diagnostic portfolio is for in vitro Diagnostic Use. Rx Only. Product(s) not available in all countries. For information on availability, please contact your local sales representative or refer to www.sciex.com/diagnostics. All other products are For Research Use Only. Not for use in Diagnostic Procedures.

Trademarks and/or registered trademarks mentioned herein, including associated logos, are the property of AB Sciex Pte. Ltd. or their respective owners in the United States and/or certain other countries (see www.sciex.com/trademarks).

© 2026 DH Tech. Dev. Pte. Ltd. MKT-38539-A.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260601890868/en/

Lulu VanZandt
Senior Manager, Brand, Public Relations and Social Media
lulu.vanzandt@sciex.com
M: +1 (508) 782-9484

Source: SCIEX